Lv1
28 积分 2024-08-25 加入
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
3个月前
已完结
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma
3个月前
已完结
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance
3个月前
已完结
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
3个月前
已完结
[The guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)]
4个月前
已完结
[Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma (2024)]
4个月前
已完结
Therapeutic progress in relapsed/refractory multiple myeloma
6个月前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
6个月前
已完结
Comparing the Efficacy and Safety of First-Line Treatments for Chronic Lymphocytic Leukemia: A Network Meta-Analysis
6个月前
已完结
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study
6个月前
已完结
皖公网安备34019202002308
